Doximity (DOCS) Stock Forecast, Price Target & Predictions
DOCS Stock Forecast
Doximity stock forecast is as follows: an average price target of $49.10 (represents a -1.60% downside from DOCS’s last price of $49.90) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
DOCS Price Target
The average price target for Doximity (DOCS) is $49.10 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $25.00. This represents a potential -1.60% downside from DOCS's last price of $49.90.
DOCS Analyst Ratings
According to 10 Wall Street analysts, Doximity's rating consensus is 'Buy'. The analyst rating breakdown for DOCS stock is 0 'Strong Buy' (0.00%), 6 'Buy' (60.00%), 3 'Hold' (30.00%), 1 'Sell' (10.00%), and 0 'Strong Sell' (0.00%).
Doximity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | Jailendra Singh | Truist Financial | $49.00 | $52.60 | -6.84% | -1.80% |
| Nov 13, 2024 | Richard Close | Canaccord Genuity | $60.00 | $35.60 | 68.54% | 20.24% |
| Nov 08, 2024 | Scott Berg | Needham | $65.00 | $57.60 | 12.85% | 30.26% |
| Nov 08, 2024 | Stan Berenshteyn | Wells Fargo | $41.00 | $42.09 | -2.59% | -17.84% |
| Nov 08, 2024 | Scott Schoenhaus | KeyBanc | $70.00 | $43.42 | 61.22% | 40.28% |
| Oct 15, 2024 | Stephanie Davis | Barclays | $52.00 | $41.96 | 23.93% | 4.21% |
| Oct 08, 2024 | Elizabeth Anderson | Evercore ISI | $45.00 | $43.22 | 4.12% | -9.82% |
| Oct 07, 2024 | Allen Lutz | Bank of America Securities | $45.00 | $43.83 | 2.67% | -9.82% |
| Aug 09, 2024 | Scott Berg | Needham | $38.00 | $25.66 | 48.09% | -23.85% |
| May 17, 2024 | Stephanie Davis | Barclays | $31.00 | $27.89 | 11.15% | -37.88% |
The latest Doximity stock forecast, released on Nov 14, 2024 by Jailendra Singh from Truist Financial, set a price target of $49.00, which represents a -6.84% decrease from the stock price at the time of the forecast ($52.60), and a -1.80% decrease from DOCS last price ($49.90).
Doximity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 5 | 8 | 14 |
| Avg Price Target | $57.00 | $53.38 | $43.64 |
| Last Closing Price | $49.90 | $49.90 | $49.90 |
| Upside/Downside | 14.23% | 6.97% | -12.55% |
In the current month, the average price target of Doximity stock is $57.00, according to 5 Wall Street analysts offering twelve months forecast. The average price target represents a 14.23% increase as opposed to Doximity's last price of $49.90. This month's average price target is up 6.78% compared to last quarter, and up 30.61% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 13, 2024 | Canaccord Genuity | - | Hold | Downgrade |
| Nov 08, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Nov 08, 2024 | KeyBanc | - | Overweight | Upgrade |
| Oct 15, 2024 | Barclays | Equal-Weight | Overweight | Upgrade |
| Oct 08, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 20, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 09, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Aug 09, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 18, 2024 | Evercore ISI | Underperform | Underperform | Hold |
| Jul 18, 2024 | Wells Fargo | Neutral | Neutral | Hold |
Doximity's last stock rating was published by Canaccord Genuity on Nov 13, 2024. The company Downgrade its DOCS rating from "null" to "Hold".
Doximity Financial Forecast
Doximity Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $135.28M | $113.61M | $108.47M | $110.97M | $115.26M | $102.19M | $90.64M | $93.65M | $97.88M | $79.35M | $72.67M |
| Avg Forecast | $148.02M | $180.88M | $162.70M | $149.92M | $136.86M | $166.84M | $149.03M | $138.46M | $124.28M | $150.10M | $127.13M | $119.88M | $116.41M | $127.50M | $109.05M | $107.00M | $110.09M | $111.28M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| High Forecast | $153.43M | $187.49M | $168.64M | $155.40M | $141.86M | $172.94M | $154.48M | $143.52M | $129.39M | $150.47M | $127.58M | $119.88M | $116.41M | $128.11M | $109.66M | $110.91M | $114.11M | $115.35M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| Low Forecast | $146.00M | $178.41M | $160.47M | $147.87M | $134.99M | $164.56M | $146.99M | $136.57M | $120.86M | $149.49M | $126.68M | $119.88M | $116.41M | $127.10M | $108.56M | $105.53M | $108.58M | $109.76M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 9 | 4 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.01% | 1.01% | 1.04% | 1.02% | 1.01% | 1.04% | 1.13% | 1.08% | 1.14% |
Doximity's average Quarter revenue forecast for Mar 24 based on 4 analysts is $116.41M, with a low forecast of $116.41M, and a high forecast of $116.41M. DOCS's average Quarter revenue forecast represents a -13.95% decrease compared to the company's last Quarter revenue of $135.28M (Dec 23).
Doximity EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 9 | 4 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $58.55M | $33.79M | $32.29M | $35.55M | $41.10M | $34.69M | $24.05M | $29.29M | $37.17M | $26.53M | $26.07M |
| Avg Forecast | $46.66M | $57.01M | $51.28M | $47.25M | $43.14M | $52.59M | $46.97M | $43.64M | $39.17M | $47.31M | $40.07M | $37.79M | $21.25M | $40.19M | $34.37M | $33.73M | $19.32M | $26.99M | $30.55M | $27.33M | $17.56M | $26.31M | $22.41M | $24.05M |
| High Forecast | $48.36M | $59.10M | $53.16M | $48.98M | $44.71M | $54.51M | $48.69M | $45.24M | $40.78M | $47.43M | $40.21M | $37.79M | $25.50M | $40.38M | $34.57M | $34.96M | $23.18M | $32.38M | $30.55M | $27.33M | $21.08M | $26.31M | $22.41M | $28.86M |
| Low Forecast | $46.02M | $56.23M | $50.58M | $46.61M | $42.55M | $51.87M | $46.33M | $43.05M | $38.10M | $47.12M | $39.93M | $37.79M | $17.00M | $40.06M | $34.22M | $33.26M | $15.46M | $21.59M | $30.55M | $27.33M | $14.05M | $26.31M | $22.41M | $19.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.46% | 0.98% | 0.96% | 1.84% | 1.52% | 1.14% | 0.88% | 1.67% | 1.41% | 1.18% | 1.08% |
4 analysts predict DOCS's average Quarter EBITDA for Mar 24 to be $21.25M, with a high of $25.50M and a low of $17.00M. This is -63.70% lower than Doximity's previous annual EBITDA (Dec 23) of $58.55M.
Doximity Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 9 | 4 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $47.96M | $30.60M | $28.41M | $30.67M | $33.47M | $26.30M | $22.38M | $36.73M | $55.65M | $36.09M | $26.32M |
| Avg Forecast | - | - | - | - | $53.22M | $70.14M | $61.12M | $55.91M | $46.02M | $65.61M | $51.12M | $44.73M | $26.66M | $47.76M | $33.61M | $28.64M | $24.24M | $40.40M | $29.99M | $19.95M | $22.04M | $22.21M | $17.34M | $24.28M |
| High Forecast | - | - | - | - | $55.75M | $73.47M | $64.03M | $58.57M | $54.02M | $74.07M | $51.33M | $44.74M | $32.00M | $49.75M | $37.34M | $30.00M | $29.09M | $48.48M | $29.99M | $19.95M | $26.44M | $22.21M | $17.34M | $29.14M |
| Low Forecast | - | - | - | - | $52.27M | $68.89M | $60.04M | $54.92M | $42.01M | $55.02M | $50.91M | $44.71M | $21.33M | $43.78M | $29.88M | $28.13M | $19.39M | $32.32M | $29.99M | $19.95M | $17.63M | $22.21M | $17.34M | $19.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.91% | 0.99% | 1.27% | 0.83% | 0.88% | 1.12% | 1.67% | 2.51% | 2.08% | 1.08% |
Doximity's average Quarter net income forecast for Mar 24 is $26.66M, with a range of $21.33M to $32.00M. DOCS's average Quarter net income forecast represents a -44.40% decrease compared to the company's last Quarter net income of $47.96M (Dec 23).
Doximity SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 9 | 4 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $44.60M | $39.17M | $43.70M | $42.91M | $42.73M | $37.77M | $36.86M | $36.54M | $34.78M | $29.99M | $26.57M |
| Avg Forecast | $56.15M | $68.61M | $61.72M | $56.87M | $51.92M | $63.29M | $56.53M | $52.52M | $47.14M | $56.94M | $48.23M | $45.48M | $26.53M | $48.36M | $41.37M | $40.59M | $24.12M | $25.25M | $37.99M | $33.99M | $21.93M | $32.72M | $27.88M | $24.51M |
| High Forecast | $58.20M | $71.12M | $63.97M | $58.95M | $53.81M | $65.60M | $58.60M | $54.44M | $49.08M | $57.08M | $48.40M | $45.48M | $31.84M | $48.60M | $41.60M | $42.07M | $28.94M | $30.30M | $37.99M | $33.99M | $26.31M | $32.72M | $27.88M | $29.41M |
| Low Forecast | $55.38M | $67.68M | $60.87M | $56.09M | $51.21M | $62.42M | $55.76M | $51.80M | $45.85M | $56.71M | $48.06M | $45.48M | $21.22M | $48.21M | $41.18M | $40.03M | $19.29M | $20.20M | $37.99M | $33.99M | $17.54M | $32.72M | $27.88M | $19.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.95% | 1.08% | 1.78% | 1.69% | 0.99% | 1.08% | 1.67% | 1.06% | 1.08% | 1.08% |
Doximity's average Quarter SG&A projection for Mar 24 is $26.53M, based on 4 Wall Street analysts, with a range of $21.22M to $31.84M. The forecast indicates a -40.51% fall compared to DOCS last annual SG&A of $44.60M (Dec 23).
Doximity EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 5 | 10 | 7 | 5 | 5 | 8 | 5 | 4 | 11 | 9 | 4 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.26 | $0.16 | $0.15 | $0.16 | $0.17 | $0.14 | $0.12 | $0.19 | $0.30 | $0.19 | $0.30 |
| Avg Forecast | - | - | - | - | $0.27 | $0.35 | $0.30 | $0.28 | $0.23 | $0.33 | $0.26 | $0.22 | $0.20 | $0.24 | $0.17 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| High Forecast | - | - | - | - | $0.28 | $0.37 | $0.32 | $0.29 | $0.27 | $0.37 | $0.26 | $0.22 | $0.20 | $0.25 | $0.19 | $0.15 | $0.18 | $0.18 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| Low Forecast | - | - | - | - | $0.26 | $0.34 | $0.30 | $0.27 | $0.21 | $0.27 | $0.25 | $0.22 | $0.20 | $0.22 | $0.15 | $0.14 | $0.17 | $0.17 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.95% | 1.05% | 0.93% | 0.97% | 0.93% | 1.20% | 1.29% | 2.69% | 2.18% | 4.71% |
According to 4 Wall Street analysts, Doximity's projected average Quarter EPS for Mar 24 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a -22.82% decrease compared to DOCS previous annual EPS of $0.26 (Dec 23).
Doximity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TDOC | Teladoc Health | $9.00 | $50.87 | 465.22% | Hold |
| ACCD | Accolade | $3.56 | $14.81 | 316.01% | Buy |
| DH | Definitive Healthcare | $4.10 | $9.50 | 131.71% | Hold |
| TXG | 10x Genomics | $13.32 | $30.20 | 126.73% | Hold |
| CERT | Certara | $9.55 | $19.33 | 102.41% | Buy |
| PGNY | Progyny | $13.98 | $25.29 | 80.90% | Hold |
| SDGR | Schrödinger | $19.17 | $28.50 | 48.67% | Buy |
| GEHC | GE HealthCare | $84.90 | $93.90 | 10.60% | Buy |
| VEEV | Veeva Systems | $210.63 | $229.71 | 9.06% | Buy |
| AMWL | American Well | $7.84 | $8.40 | 7.14% | Hold |
| DOCS | Doximity | $49.90 | $49.10 | -1.60% | Buy |
| HQY | HealthEquity | $102.96 | $97.00 | -5.79% | Buy |